Cost-Effectiveness of brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma

Brexucabtagene autoleucel is a chimeric anti CD19 antigen receptor T-cell therapy that allows durable responses in relapsed/refractory (R/R) mantle cell lymphoma (MCL). The present study compared the clinical and economic outcomes of R/R MCL patients (pre-exposed to ibrutinib and chemoimmunotherapy)...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia & lymphoma 2023-07, Vol.ahead-of-print (ahead-of-print), p.1-9
Main Authors: Marchetti, M., Visco, C.
Format: Article
Language:English
Subjects:
Adult
Antineoplastic Agents - therapeutic use
brexucabtagene autoleucel
CD19 antigens
Chimeric antigen receptor T-cell
Cost-Benefit Analysis
cost-effectiveness
Humans
Immunotherapy, Adoptive - methods
Lymphoma, Mantle-Cell - drug therapy
Lymphoma, Mantle-Cell - pathology
mantle cell lymphoma
relapsed refractory mantle cell lymphoma
T-cell therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Brexucabtagene autoleucel is a chimeric anti CD19 antigen receptor T-cell therapy that allows durable responses in relapsed/refractory (R/R) mantle cell lymphoma (MCL). The present study compared the clinical and economic outcomes of R/R MCL patients (pre-exposed to ibrutinib and chemoimmunotherapy) treated with brexucabtagene autoleucel versus Rituximab, bendamustine, cytarabine (R-BAC) in the Italian Healthcare System. A partitioned-survival model extrapolated survival and healthcare costs of R/R MCL patients over a lifetime horizon. Discounted and quality-adjusted life expectancy (QALY) was 6.40 versus 1.20 for brexucabtagene autoleucel versus R-BAC and lifetime costs were €411,403 versus €74,415, respectively, which corresponds to a cost of €64,798 per QALY gained. The results were highly sensitive to brexucabtagene autoleucel acquisition cost and to assumptions on long-term survival, therefore the cost-effectiveness of brexucabtagene autoleucel for patients with R/R MCL requires validation with longer follow-up data and in specific risk subgroups.
ISSN:1042-8194
1029-2403
DOI:10.1080/10428194.2023.2215888